Genetron Health and West China Hospital's cooperation project for early precision diagnosis and treatment of lung cancer won the second prize of National Science and Technology Progress Award

Beijing, November 3, 2021/PRNewswire/ - Today, Generic Health (Nasdaq: GTH) and West China Hospital of Sichuan University collaborated in-depth on the “Establishment and Clinical Application of Key Technologies for Early Accurate Diagnosis of Lung Cancer”.

The project was led by Professor Li Weimin from West China Hospital of Sichuan University, with the in-depth participation of the Genetron Health team.

Aiming at the difficult problem of accurate diagnosis and treatment of early lung cancer, the project team used the patented technology "one-step method for rapid construction of amplicon library" (Chinese invention patent ZL201710218529.

Project data shows that in terms of accuracy, Genetron Health’s “one-step” patented technology is at the level of 10ng DNA starting amount, and the accuracy rate for 3% mutation detection is 100%; at the 30ng RNA starting amount level, for 100 copies of the mutation.

In terms of accessibility-ease of use and economic cost, the use of "one-step" technology can avoid multiple opening operations, prevent potential pollution, and shorten the construction time from the traditional 1-2 days to only 1.

Human 8-gene mutation joint detection kit (semiconductor sequencing method) (National Machinery Note 20203400072)

In this project, Genetron Health's "Human 8-Gene Mutation Joint Detection Kit (Semiconductor Sequencing Method) (National Machinery Note 20203400072)" equipped with the "one-step method" played a huge role.

Wang Sizhen, co-founder and CEO of Genetron Health, said: "I am very proud that Genetron Health's original technology and products can help clinical innovation and have been recognized by national awards

About the National Science and Technology Progress Award

The National Science and Technology Progress Award is one of the five national science and technology awards established by the State Council (the highest national science and technology award, the national natural science award, the national technological invention award, the national science and technology progress award, and the international science and technology cooperation award)

The National Science and Technology Progress Award is mainly awarded to Chinese citizens and organizations who have made creative contributions in the process of technological research, technological development, technological innovation, promotion and application of advanced scientific and technological achievements, promotion of high-tech industrialization, and completion of major scientific and technological projects and plans.

About Panshengzi

Generic Health (Nasdaq: GTH) is a global cutting-edge cancer precision medicine company, focusing on cancer genomics research and application, and is committed to changing the way of cancer diagnosis and treatment relying on advanced molecular biology and big data analysis capabilities

Safe Harbor Statement

This press release contains Genetron Health's future expectations, plans and forward-looking statements, which are subject to corresponding risks and uncertainties, which may cause actual results to differ from the expectations described in the forward-looking statements

Source: Genetron Health